Reclast (Zoledronic Acid) Side Effects: Who Gets the Worst Reactions and Why

What Is Zoledronic Acid and Why Do Women Use It?

Zoledronic acid, sold as Reclast in the United States, is an intravenous bisphosphonate given as a single 5 mg infusion once a year. It is the most potent nitrogen-containing bisphosphonate available and is FDA-approved for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease of bone, and osteoporosis in men. Women account for the large majority of patients receiving it, given the steep rise in bone loss that follows menopause.

The drug works by binding to bone mineral and inhibiting osteoclast-mediated resorption. A single dose suppresses bone turnover markers within days and maintains that suppression for 12 months or longer. Because it is given intravenously, you absorb close to 100% of the dose, which is both its therapeutic advantage over oral bisphosphonates and the reason its side-effect profile differs in important ways.

The Acute-Phase Reaction: The Side Effect Most Women Experience

The acute-phase reaction (APR), sometimes called a post-infusion flu, is by far the most common adverse event. It typically begins 24-48 hours after the infusion and resolves within 72 hours in most women.

What the HORIZON-PFT Trial Actually Found

The landmark HORIZON Key Fracture Trial (HORIZON-PFT), which enrolled 7,736 postmenopausal women with osteoporosis, found that 31.6% of patients in the zoledronic acid group reported an acute-phase reaction after dose 1, compared with 6.2% in the placebo group. By year 2, that rate dropped to 6.6%, and by year 3 it was 2.8%. The body essentially adapts. Fever, myalgia, arthralgia, and headache were the four dominant symptoms in that order.

Why the Second and Third Infusions Are Easier

Repeated exposure down-regulates the gamma-delta T-cell expansion that drives the acute inflammatory cascade. For women who had a moderate or severe APR with dose 1, that experience does not predict the same severity with dose 2. Reassuring women of this trajectory, rather than letting them discontinue therapy, matters clinically.

Which Women Have the Worst First-Dose Reactions?

Several phenotypic features predict APR severity, and most are modifiable.

Vitamin D deficiency. Low 25-hydroxyvitamin D amplifies the inflammatory response. Correcting vitamin D to at least 20 ng/mL, and ideally 30 ng/mL, before infusion is consistently recommended in The Menopause Society's 2023 position statement on osteoporosis pharmacotherapy. Most clinicians recommend 1,000-2,000 IU daily for at least 2 weeks beforehand in replete patients, and higher doses for deficient ones.

First-time bisphosphonate use. Women who have never taken an oral bisphosphonate have more available nitrogen-sensing receptors in circulating monocytes and gamma-delta T cells. Prior exposure to alendronate or risedronate meaningfully blunts the APR.

Younger postmenopausal age. Data from HORIZON-PFT and from a 2019 post-marketing analysis published in Osteoporosis International show that women within 5 years of their final menstrual period have higher APR rates than women who are 10 or more years postmenopausal. The reason is not fully established, but higher baseline bone turnover in early postmenopause may be part of the mechanism.

Higher baseline C-reactive protein. Inflammatory phenotypes, including women with active rheumatoid arthritis or lupus, tend toward more severe reactions.

Kidney Function: The Contraindication That Matters Most

Zoledronic acid is renally cleared. The FDA label prohibits use in patients with creatinine clearance below 35 mL/min. This is not a soft caution. Administering the drug to a woman with stage 3b-5 chronic kidney disease can precipitate acute kidney injury and prolonged hypocalcemia, both of which become serious within 24-48 hours.

Why Women Need Kidney Assessment at Every Infusion

Kidney function in women is not static. Three life situations change it rapidly:

1. Perimenopause and early postmenopause. Estrogen supports renal tubular function. The estrogen withdrawal of menopause modestly reduces GFR in some women, so a woman who cleared the eGFR threshold at age 55 may not at age 62.

2. Dehydration on infusion day. Nonsteroidal anti-inflammatory drugs taken to pretreat the APR can reduce renal perfusion acutely. Administering zoledronic acid to a dehydrated patient, even one with normal baseline kidney function, increases the risk of a transient creatinine rise. Ensure 500 mL of oral hydration in the 2 hours before infusion.

3. NSAID-containing premedication. Ibuprofen 400-600 mg is commonly prescribed before infusion to blunt the APR. On infusion day, that dose is generally safe if the patient is well-hydrated and has normal renal function. In women with borderline eGFR of 40-50 mL/min, acetaminophen is the safer premedication choice.

Hypocalcemia: The Silent Post-Infusion Risk

Transient hypocalcemia occurs in roughly 17% of patients after zoledronic acid infusion and can be severe enough to cause symptomatic tetany in women with pre-existing hypocalcemia or hypoparathyroidism. Most cases are asymptomatic and resolve within days, but the risk is highest in the first 24-48 hours.

Women at particular risk include those with:

• Untreated vitamin D deficiency (the most preventable cause)
• Primary hypoparathyroidism
• Malabsorption syndromes reducing calcium intake
• Celiac disease, which disproportionately affects women

Check serum calcium and 25-hydroxyvitamin D before every infusion, not just the first. Supplement calcium carbonate 500 mg twice daily for at least the first 2 weeks after infusion if dietary intake is below 1,000 mg per day.

Osteonecrosis of the Jaw: Real Risk or Overblown Fear?

Osteonecrosis of the jaw (ONJ) is the adverse event women most often bring to clinical discussions, frequently after reading forum posts. The actual risk at osteoporosis doses is far lower than the risk associated with oncologic doses.

A clinically useful way to frame this is the phenotype-stratified risk ladder:

| Patient Phenotype | Estimated ONJ Risk per Year | |---|---| | Postmenopausal osteoporosis, no dental disease | 1 in 100,000 to 1 in 10,000 | | Osteoporosis with active periodontal disease | Elevated; exact rate poorly characterized | | Cancer patient on monthly oncologic dosing | 1 in 100 to 1 in 10 |

The American Association of Oral and Maxillofacial Surgeons position paper confirms that invasive dental procedures are the primary precipitating factor. Women planning tooth extractions or implants should complete that dental work before starting zoledronic acid, or wait until the bone remodeling suppression from their last infusion has meaningfully waned, generally 2 or more years for annual dosing.

Risk rises with cumulative duration of therapy. A 2020 systematic review in the Journal of Bone and Mineral Research found that ONJ incidence in osteoporosis patients increased with treatment duration beyond 4 years, though absolute numbers remained low. Annual dental review is standard practice for any woman on long-term zoledronic acid.

Atypical Femur Fracture: Duration-Dependent and Identifiable

Atypical femur fracture (AFF) is a stress fracture of the subtrochanteric or diaphyseal femur that occurs with minimal or no trauma. It is a class effect of all bisphosphonates, including zoledronic acid.

The FDA strengthened its AFF warning for bisphosphonates in 2010 and updated it in 2011, and the risk is duration-dependent. A 2011 case-control study in NEJM by Schilcher et al. found that the risk of AFF rose sharply after 3 years of bisphosphonate use and was highest in women who had taken the drug for 5 or more years.

Warning Signs Women Should Know

Classic prodromal symptoms include dull, aching thigh or groin pain that is present at rest and worsens with weight-bearing. This pain often precedes fracture by weeks to months. Any woman on year 4 or beyond of zoledronic acid who reports this pain warrants bilateral femur X-rays, not a reassurance that it is arthritis.

Drug Holidays: When and for Whom

The American Society for Bone and Mineral Research (ASBMR) 2016 task force report recommends considering a drug holiday after 3 years of zoledronic acid in women at lower fracture risk, defined as having a T-score above -2.5 at the hip and no prior vertebral fractures. For women at higher risk, continuing therapy is generally appropriate through year 6, with reassessment at that point. A drug holiday does not mean fracture protection disappears immediately; residual suppression of bone turnover persists for 18-24 months after the last infusion, longer than for any oral bisphosphonate.

Musculoskeletal Pain: Underreported and Underconnected

Severe, incapacitating bone, joint, or muscle pain is listed in the Reclast prescribing information as a rare adverse event, and the FDA issued a black-box-adjacent safety communication about this in 2008 for the bisphosphonate class. Onset can be delayed from days to months after the first infusion, which makes the drug-symptom connection difficult for both women and clinicians.

Women with fibromyalgia or a history of inflammatory arthritis may be at higher risk of this delayed musculoskeletal pain phenotype. If severe pain begins after infusion with no other explanation, a trial of discontinuation is diagnostic: symptoms resolve in most cases within days to weeks of stopping.

Atrial Fibrillation: What the Signal Means for You

An excess of serious atrial fibrillation (AF) was reported in the HORIZON-PFT trial, appearing in 1.3% of the zoledronic acid group versus 0.5% in placebo. This generated significant post-market scrutiny. Subsequent analyses, including a large Danish registry study published in JAMA Internal Medicine, did not confirm a consistent association. Current consensus is that the HORIZON-PFT finding may have been a statistical artifact or related to infusion-related electrolyte shifts rather than a direct drug effect.

For women who already have AF or are at high risk because of structural heart disease, hypertension, or hyperthyroidism, this remains an area of clinical judgment. Discuss it with your cardiologist before infusion rather than dismissing the concern entirely.

Ocular Side Effects: Rare but Worth Mentioning

Uveitis, scleritis, episcleritis, and conjunctivitis have been reported post-infusion, generally occurring within 1-48 hours. They are uncommon, estimated at less than 1% of infusions in post-market case series reviewed by the Canadian Adverse Drug Reaction Monitoring Program. Red, painful eye after infusion that does not resolve within 24 hours warrants same-day ophthalmology assessment, not watchful waiting.

Pregnancy, Lactation, and Contraception: A Required Discussion

Zoledronic acid is contraindicated in pregnancy. It is classified as FDA Pregnancy Category D, based on animal studies showing fetal hypocalcemia, delayed ossification, and intrauterine death at doses comparable to human exposure. Human data are limited to case reports, not controlled trials, but the teratogenic mechanism, disruption of fetal bone mineralization, is biologically plausible and serious.

Bisphosphonates deposit into maternal bone and can slowly release over years. This means a woman who receives zoledronic acid and then conceives months or years later may still have detectable circulating drug. The clinical significance of this skeletal reservoir for fetal outcomes is not well characterized, which itself is a reason for caution. A 2019 review in Osteoporosis International identified 78 pregnancies with bisphosphonate exposure in the literature and found adverse outcomes including neonatal hypocalcemia in a subset, though confounding by underlying conditions was present in most cases.

Reliable contraception is required for any woman of reproductive potential who receives zoledronic acid. The drug half-life in bone is estimated at up to 10 years, so the concept of a standard washout period that makes the drug "safe to try to conceive" does not apply cleanly. Women who are planning pregnancy within 2-3 years should discuss alternative approaches to bone protection with their clinician, such as calcium and vitamin D optimization and weight-bearing exercise, rather than initiating zoledronic acid.

Lactation. No human lactation data exist for zoledronic acid. Because the drug is highly protein-bound, has limited oral bioavailability, and binds rapidly to bone mineral, systemic infant exposure through breast milk is expected to be low. However, the complete absence of human milk transfer data, combined with the drug's serious mechanism of action, means most clinicians advise against breastfeeding after infusion until more data exist. LactMed currently lists zoledronic acid as having no published human data.

Women who receive zoledronic acid for premenopausal osteoporosis (a less common but real indication in women with low bone density related to eating disorders, amenorrhea, or glucocorticoid use) need explicit contraception counseling at every visit, not just at initiation.

Who This Drug Is Right For, and Who Should Pause

Women Who Tend to Benefit Most

• Postmenopausal women with a T-score at or below -2.5 at the hip or spine
• Women who cannot tolerate or absorb oral bisphosphonates because of esophageal disease, bariatric surgery (particularly gastric bypass), or GI intolerance
• Women with high fracture risk requiring reliable adherence, since a once-yearly infusion removes the weekly pill burden that leads to oral bisphosphonate non-adherence
• Women on chronic glucocorticoids for autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) who have developed glucocorticoid-induced osteoporosis

Women Who Should Wait or Choose an Alternative

• Any woman with eGFR <35 mL/min/1.73 m²
• Pregnant women or those planning conception within 1-2 years
• Women with untreated hypocalcemia or vitamin D deficiency below 20 ng/mL (correct first, then reassess)
• Women with active dental infection or planned invasive dental work within 3 months
• Women with a history of hypersensitivity to any bisphosphonate

Premedication and Supportive Care: What the Evidence Supports

Acetaminophen 1,000 mg taken 30-60 minutes before infusion and continued every 6 hours for 24-48 hours reduces APR severity in most women. A randomized trial by Reid et al. confirmed that acetaminophen premedication significantly reduced the proportion of patients with post-infusion fever compared to placebo. Ibuprofen 400 mg is an alternative for women without renal or GI contraindications.

Adequate hydration (at least 500 mL of fluid before the infusion) reduces the risk of transient creatinine elevation. The infusion itself should run over at least 15 minutes, never faster, because rapid infusion directly correlates with nephrotoxicity risk.

A Note on Evidence Gaps in Women

The HORIZON-PFT trial enrolled only postmenopausal women, so its safety data are directly applicable to that population. For premenopausal women with osteoporosis, the safety database is substantially thinner. No large randomized trial has examined zoledronic acid adverse event frequency or severity specifically in perimenopausal women (the years of irregular cycles before the final menstrual period), a group increasingly receiving bone-protection therapy because of early bone loss. The Endocrine Society's 2019 guideline on premenopausal osteoporosis acknowledges this gap explicitly, noting that bisphosphonate use in premenopausal women is largely extrapolated from postmenopausal data.

Women have been under-represented in trials examining long-term bisphosphonate safety, particularly for the AFF and ONJ endpoints, because those events are rare and require very large samples or long follow-up to detect reliably. Much of what is known about phenotypic predictors of these serious events comes from registries and post-market surveillance rather than randomized trials, which introduces the usual limitations of confounding and reporting bias.